Skip to main content
. Author manuscript; available in PMC: 2021 Dec 8.
Published in final edited form as: Clin Cancer Res. 2021 Feb 4;27(9):2648–2662. doi: 10.1158/1078-0432.CCR-20-2961

Figure 6. The therapeutic effect of VX-702 as a single agent or adjuvant to everolimus in the WHIM 11J PDX model with de novo tamoxifen resistance.

Figure 6.

(a) WHIM 11J PDX tumors were transplanted into ovariectomized female nude mice in the absence of estrogen or tamoxifen supplementation. Upon tumor establishment, mice were randomized into four treatment arms: vehicle, VX-702 (50mg/kg, o.g BID), everolimus (Eve, 5 mg/kg, o.g daily), or VX-702+everolimus. Left: the average tumor volumes of each treatment group. Right: the tumor volumes of different treatment arms on Day 22. The Boxplot illustrates the distribution of the tumor volumes of each treatment group based on the following: minimum, first quartile, median, third quartile, the maximum, and the outliers. The error bars represent the standard deviations. (b) Kaplan-Meier survival plot comparing the progression-free survival of different treatment arms. Progression-free survival was analyzed based on tumor-tripling time. (c) The body weight measurements of mice in different treatment arms. *P<0.05; **P<0.01; *** P<0.001. P-values were calculated based on two-way mixed ANOVA for comparing the tumor volumes and generalized Wilcoxon test for progression-free survival.